Cytokinetics announces topline results from METEORIC-HF Read more about Cytokinetics announces topline results from METEORIC-HF
Cytokinetics announces start of SEQUOIA-HCM, a phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy Read more about Cytokinetics announces start of SEQUOIA-HCM, a phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy
Cytokinetics announces FDA acceptance of new drug application for omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction Read more about Cytokinetics announces FDA acceptance of new drug application for omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction
Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis Read more about Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis
EVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19 Read more about EVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19
Bristol Myers Squibb Announces New PDUFA Date for Mavacamten Read more about Bristol Myers Squibb Announces New PDUFA Date for Mavacamten
US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction Read more about US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction
AZD7442 reduced risk of developing severe COVID-19 or death in TACKLE Phase III outpatient treatment trial Read more about AZD7442 reduced risk of developing severe COVID-19 or death in TACKLE Phase III outpatient treatment trial
Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction Read more about Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19 Read more about AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19
